Canada’s Drug Agency (CDA) has issued its Draft Reimbursement Recommendation for Teprotumumab (Tepezza) for Thyroid Eye Disease (TED) with a decision “not to reimburse”.  This decision, if upheld, would significantly restrict access to Tepezza for Canadian patients.  This includes all TED patients who rely on public drug insurance, except those in Quebec, and some patients whose private insurers follow CDA’s recommendation.  See complete report at SR0853-Tepezza_DRAFT_Rec.pdf.

The Thyroid Foundation of Canada (TFC) is preparing a strong response to CDA to highlight TED patients’ unmet treatment needs and urge them to reconsider our submission.  Responses from TFC, clinical groups and Amgen are due on June 5^th, 2025.  The final decision will be in the next CDA Reimbursement Recommendation report which is expected in the fall.